Abstract 758P
Background
Vulvar and vaginal squamous cell carcinoma (VVSCC) are rare, representing 4% of gynecologic cancers. At recurrent/metastatic stage systemic treatments are limited without gold-standard, chemotherapy response rate is poor. Immunotherapy has been approved for some metastatic SCC. Translational analyzes suggest that SCC share common molecular features as epigenetic. Modulating the epigenome might improve the efficacy of immunotherapy. Combining pembrolizumab (P) to an epidrug vorinostat (V) has been proposed in the PEVO basket trial. We described here the VVSCC cohort.
Methods
PEVOsq is an open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of P combined to V in patients with recurrent/metastatic SCC of the cervix, head and neck, anus, vulva/vagina, penis, and lung. Patients had to be PD1/PD-L1 antagonist-naïve. There was no selection based on PD-L1 expression, HPV status, or number of prior lines of treatments. P dose was 200 mg Q3W IV, and V 400 mg QD PO. Sample size was determined using an A’Hern design with the following hypotheses (alpha=5%, power=90%, p0=5%, p1=30%). The primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS).
Results
Among 112 included patients, 17 had a VVSCC metastatic/recurrent cancer. Median age was 63 years old [range: 40-85], 14 (82.4%) had a metastatic disease and 3 (17.6%) a locally advanced relapse. Lung 50.0%) and lymph nodes (78.6%) were the major metastatic sites. Inclusion in PEVOsq was the first-line treatment for most of patients, with a median number of prior treatment lines of 0 [range: 0-1]. Three patients out of 16 evaluable patients (18.8%) had an OR: 1 (6.3%) CR and 2 (12.5%) PR. Median PFS was 1.3 months [95%CI: 1.1-4.3]. Median OS was 17.5 months [95%CI: 2.3-NR]. Four patients (23.5%) had a G3/4 treatment related AE. Results according to PDL1, MSI, TMB and HPV will be presented at the meeting.
Conclusions
P combined with V is safe and produce encouraging efficacy in VVSCC patients.
Clinical trial identification
NCT04357873, EudraCT 2019-003839-33.
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
ERA PerMED and Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11